Skip to content

Protected: Studies

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Orcrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients with Relapsing Multiple Scler

Calendar Name Opera
Description The primary objective of this study is to assess whether the efficacy of ocrelizumab 600 mg (given as dual infusions of 300 mg on Days 1 and 15 of the first 24-week treatment cycle and as a single inf
PI Bruce Cohen
People Joy Derwenskus | Patricia Casey
Business Administrator -
Resources 3T Trio
IRB 00050269
Start Date 2012-06-01
End Date 2015-12-31
Chart String 640-5210600-60031015
Affiliates No